{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-015069","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2023-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.647187+00:00","generated_at":"2026-06-07T19:38:29.804579+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tenax Therapeutics shareholders approve reverse stock split authorization","bullets":["Reverse split ratio range 1:10 to 1:80, exact ratio set by board; authorized until Nov 30, 2024.","For: 6,198,812; Against: 5,364,151; Abstain: 23,186; no broker non-votes.","Adjournment proposal also approved (6,308,531 for, 5,052,193 against) but not used."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-015069","json":"https://secwatch.observer/filing/0001654954-23-015069.json","markdown":"https://secwatch.observer/filing/0001654954-23-015069.md","text":"https://secwatch.observer/filing/0001654954-23-015069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000165495423015069/0001654954-23-015069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000165495423015069/tenx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T19:38:29.804579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4e09a7b0065ae9b0411112870d69ecdeb3ae4e51","claim":"TENAX THERAPEUTICS, INC. shareholders approved Approve amendment to certificate of incorporation to authorize a reverse stock split at the 2023-11-30 meeting.","evidence_excerpt":"The vote for this proposal was 6,198,812 shares for, 5,364,151 shares against, 23,186 shares abstaining, and no broker non-votes.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/34956/000165495423015069/0001654954-23-015069-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-30"}],"fact_type":"shareholder_vote"},{"claim_id":"8c4ef3e1a7c1b4682dd891080fddb1a293f6fcb6","claim":"TENAX THERAPEUTICS, INC. shareholders approved Adjournment of Special Meeting to permit further solicitation and vote of proxies at the 2023-11-30 meeting.","evidence_excerpt":"The Adjournment Proposal was approved at the Special Meeting, with a vote of 6,308,531 shares for, 5,052,193 shares against, 225,425 shares abstaining, and no broker non-votes.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/34956/000165495423015069/0001654954-23-015069-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-11-30"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}